Medical News Today: Way to prevent chemotherapy hair loss in sight

Using a mini organ model, scientists reveal how taxane chemotherapy can permanently damage hair follicles, and how a newer class of drug could prevent it.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Dermatology Source Type: news

Related Links:

Skin Toxicity: Clinical Summary of the ONS Guidelines™ for Cancer Treatment-Related Skin Toxicity. Clin J Oncol Nurs. 2020 Oct 01;24(5):561-565 Authors: Wiley K, Ebanks GL, Shelton G, Strelo J, Ciccolini K Abstract Cancer treatment-related skin toxicities are a frequent and distressing side effect of antineoplastic therapies, especially chemotherapy and targeted therapies. Skin toxicities associated with these therapies can include rashes, hand-foot skin reaction, hand-foot syndrome, and hair loss. These symptoms cause not only physical pain and discomfort but also psychological distress, and th...
Source: Clinical Journal of Oncology Nursing - Category: Nursing Authors: Tags: Clin J Oncol Nurs Source Type: research
Conditions:   Alopecia;   Chemotherapy-Induced Change;   Hair Loss;   Alopecia Drugs Intervention:   Drug: Keratinocyte growth factor Sponsor:   University of Arizona Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
CONCLUSIONS: Severe CIA occurred in all 68 patients who received FEC and taxane chemotherapy. The present findings provide the first data demonstrating that age was not associated with the degree or incidence of hair loss, but age affected the recovery from CIA. These results contribute more accurate information provision and insights regarding the proper treatment of CIA. PMID: 32944881 [PubMed - as supplied by publisher]
Source: Breast Cancer - Category: Cancer & Oncology Authors: Tags: Breast Cancer Source Type: research
CONCLUSION: The results of current study showed that in patients with advanced gastric adenocarcinoma, FOLFOX regimen compared to mDCF regimen have similar ORR, OS and PFS. Toxicity rate are also lower in FOLFOX group, thus it seems a better regimen for chemotherapy.. PMID: 32856863 [PubMed - as supplied by publisher]
Source: Asian Pacific Journal of Cancer Prevention - Category: Cancer & Oncology Tags: Asian Pac J Cancer Prev Source Type: research
ONS Guidelines™ for Cancer Treatment-Related Skin Toxicity. Oncol Nurs Forum. 2020 Sep 01;47(5):539-556 Authors: Williams LA, Ginex PK, Ebanks GL, Ganstwig K, Ciccolini K, Kwong BK, Robison J, Shelton G, Strelo J, Wiley K, Maloney C, Moriarty KA, Vrabel M, Morgan RL Abstract BACKGROUND: Management of cancer treatment-related skin toxicities can minimize treatment disruptions and improve patient well-being. OBJECTIVES: This guideline aims to support patients and clinicians in decisions regarding management of cancer treatment-related skin toxicities. METHODS: A panel developed a guideli...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
Abstract PROBLEM IDENTIFICATION: Preventing and managing skin toxicities can minimize treatment disruptions and improve well-being. This systematic review aimed to evaluate the effectiveness of interventions for the prevention and management of cancer treatment-related skin toxicities. LITERATURE SEARCH: The authors systematically searched for comparative studies published before April 1, 2019. Study selection and appraisal were conducted by pairs of independent reviewers. DATA EVALUATION: The random-effects model was used to conduct meta-analysis when appropriate. SYNTHESIS: 39 studies (6,006 patie...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
Abstract Modern anticancer drugs target DNA specifically on rapid division of malignant cells. One downside of this approach is that they also target other rapidly dividing healthy cells such as those involved in hair growth leading to serious toxic side effects and hair loss. Therefore, it would be better to develop novel agents that address cellular signalling mechanisms unique to cancerous cells, and new research is now focussing on such approaches. Although the classical chemotherapy area involving DNA as the set target continues to produce important findings, nevertheless, a distinctly discernible emerging tr...
Source: Current Topics in Medicinal Chemistry - Category: Chemistry Authors: Tags: Curr Top Med Chem Source Type: research
CONCLUSION: Andecaliximab in combination with gemcitabine and nab-paclitaxel demonstrates a favorable safety profile and clinical activity in patients with advanced pancreatic adenocarcinoma. IMPLICATIONS FOR PRACTICE: The combination of andecaliximab, a novel, first-in-class inhibitor of matrix metalloproteinase 9, with gemcitabine and nab-paclitaxel in patients with advanced pancreatic adenocarcinoma provided a median progression-free survival of 7.8 months and objective response rate of 44.4%. The majority of systemic biomarkers related to matrix metalloproteinase 9 activity and immune suppression increased at 2 mo...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
FINDINGSUCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone. In a nationwide analysis of nearly 20,000 patients whose cancer had not yet spread to other organs, the scientists learned that only 22% were treated with some form of chemotherapy.The researchers found that even among patients with the largest and most aggressive tumors, less than half (45%) received chemotherapy. The team also found that patients were more likely to be treated with chemotherapy at facilities that perform at least 55 surgeries for sarcom...
Source: UCLA Newsroom: Health Sciences - Category: Universities & Medical Training Source Type: news
A major concern among patients with cancer is hair loss secondary to chemotherapy, an adverse effect that occurs among approximately 65% of patients who undergo this form of therapy. The association between chemotherapy and hair loss is well known across society, and chemotherapy-induced alopecia (CIA) can, therefore, induce a sense of violated privacy, or even shame, among those affected. The association of this adverse effect with reduced self-esteem, social confidence, and sexuality is particularly devastating for women. The anticipation of CIA is so distressing that some female patients even seriously consider refusing...
Source: JAMA Dermatology - Category: Dermatology Source Type: research
More News: Alopecia | Chemotherapy | Dermatology | Eyes | Health | Skin